Advanced Search:
Equity Index Forex Crypto Commodity

ARGX - argenx SE

$378.02  -1.63 (-0.43%)

Updated: 03:14 May 5, 2024 EST

Next Hour's AI Forecast

99.35%

Avg. Accuracy (AI)

$397.1

Next Session's AI Forecast

96.59%

Avg. Accuracy (AI)

$381.76

Next Week's AI Forecast

83.33%

Trend's Accuracy (AI)

$376

argenx SE's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

ARGENX SE - HISTORICAL DATA 6M

  • Last price

    $ 378.02

  • Daily change

    $ -1.63

  • Previous Close

    $ 379.65

  • Last Updated

    03:14 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.91 0.09 -0.01 -0.22 -0.01

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.8 1.17 1.31 1.72 1.61

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 100% 100% 67.89%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
396.3 4.53% 379.14 -1.02% 383.04 -6.75% 410.77

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.25 32.43 2.68 20

argenx SE Technical Analysis News

argenx SE

Laarderhoogtweg 25
Amsterdam 1101EB
Netherlands
31 10 703 8441
https://www.argenx.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 1148
Description

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Corporate Governance

argenx SE’s ISS Governance QualityScore as of May 1, 2024 is 4. The pillar scores are Audit: 3; Board: 2; Shareholder Rights: 3; Compensation: 9.

ARGENX SE'S HOLDERS RANK

List of holders with stock participation in argenx SE.

Holder Rank Holder Shares Date Reported % Out Value